PDF(Pubmed)
Abstract：
The complement cascade is a vital system in the human body\'s defense against pathogens. During the natural aging process, it has been observed that this system is imperative for ensuring the integrity and homeostasis of the retina. While this system is critical for proper host defense and retinal integrity, it has also been found that dysregulation of this system may lead to certain retinal pathologies, including geographic atrophy and diabetic retinopathy. Targeting components of the complement system for retinal diseases has been an area of interest, and in vivo, ex vivo, and clinical trials have been conducted in this area. Following clinical trials, medications targeting the complement system for retinal disease have also become available. In this manuscript, we discuss the pathophysiology of complement dysfunction in the retina and specific pathologies. We then describe the results of cellular, animal, and clinical studies targeting the complement system for retinal diseases. We then provide an overview of complement inhibitors that have been approved by the Food and Drug Administration (FDA) for geographic atrophy. The complement system in retinal diseases continues to serve as an emerging therapeutic target, and further research in this field will provide additional insights into the mechanisms and considerations for treatment of retinal pathologies.
摘要：
补体级联是人体防御病原体的重要系统。在自然老化过程中,已经观察到，该系统对于确保视网膜的完整性和稳态是必不可少的。虽然该系统对于适当的宿主防御和视网膜完整性至关重要，还发现该系统的失调可能导致某些视网膜病变，包括地理萎缩和糖尿病性视网膜病变。视网膜疾病的补体系统的靶向成分一直是一个令人感兴趣的领域，在体内，离体,在这方面已经进行了临床试验。经过临床试验,针对视网膜疾病的补体系统的药物也已经可用。在这份手稿中,我们讨论了视网膜补体功能障碍的病理生理学和具体病理。然后我们描述细胞的结果，动物,以及针对视网膜疾病的补体系统的临床研究。然后，我们提供了已被食品和药物管理局（FDA）批准用于地理萎缩的补体抑制剂的概述。视网膜疾病中的补体系统继续作为一个新兴的治疗目标，在这一领域的进一步研究将为视网膜病变的治疗机制和考虑提供更多的见解。
